plantation of unrelated stem cells may be a further alternative. However, it is limited by a high risk of graft rejection and graft-versus-host disease (GVHD). [1] [2] [3] [4] [5] To overcome these problems, megadoses of unrelated highly purified peripheral CD34
+ cells were used in this study. Magnetic cell sorting (MACS) was performed to purify the peripheral blood mononuclear cells with adequate recovery of CD34 + cells. 6 We present the clinical, hematopoietic and immunologic data of three children who underwent transplantation with 'megadoses' of unrelated purified CD34
+ cells for the treatment of refractory SAA.
Patients and methods

Patients
Patients enrolled in this study previously failed immunosuppressive treatment and did not have an appropriate HLA-matched sibling or related donor. In all patients, Fanconi anemia was excluded by diepoxybutane testing of peripheral blood lymphocytes for increased chromosome breakage. Patient 1 presented with constitutional SAA at the age of 3 months, and did not respond to various immunosuppressive agents within 3 years, including repeated courses of antilymphocyte globulin (ALG), cyclosporin A (CsA) and methylprednisone (MP) as well as to stimulation of hematopoiesis with filgrastim, erythropoietin and huR-IL-3. He underwent splenectomy but remained erythrocyte and platelet transfusion-dependent. Patient 2 also suffered from constitutional SAA. He did not respond to similar immunosuppressive treatments as patient 1. After conditioning with cyclophosphamide (200 mg/kg) and ALG, the patient received a 5/6 HLA-matched (C-locusmismatched) umbilical cord blood (UCB) graft. After initial engraftment he showed graft rejection and autologous reconstitution by day +45 and remained erythrocyte and platelet transfusion-dependent. Patient 3 suffered from acquired SAA and did not respond to ALG, CSA and MP. Patients characteristics are summarized in Table 1 .
Unrelated donor selection, mobilization and collection of stem cells
International search for potential unrelated donors was performed by the 'Austrian Bone Marrow Donor Registry' and 
Magnetic positive selection of CD34 + cells
In patient 1 positive selection of CD34 + cells was performed using the CD34 + Progenitor Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) applying a magnetic cell separation (MACS) technique using the Super-MACS sorting device (Miltenyi Biotec) according to the manufacturer's instructions. [6] [7] [8] In the other two cases CD34 + cells were selected using the CliniMACS-system (Miltenyi Biotec). Apheresis products were diluted (1:1) in buffer solution consisting of phosphate-buffered saline (PBS) w/o Ca/Mg (Gibco, Paisley, UK), 5 mm EDTA and 5% human albumin at a final concentration of 0.8% (Immuno, Vienna, Austria) and centrifuged for 15 min at 350 g for removal of platelets. Then, sedimented cells were resuspended in the same buffer solution at 2 ϫ 10 8 nucleated cells (NC)/ml and incubated with 5 mg 7-Simmunoglobulin/10 11 NC for 5 min at room temperature to block nonspecific Fc-receptors. Thereafter 7.5 ml of Clini-MACS CD34 Reagent (Miltenyi Biotec) was added to 5 ϫ 10 10 NC and incubated for 30 min at room temperature. Then, antibody-labeled cells were resuspended in buffer solution to a final concentration of р2 ϫ 10 8 NC/ml and transferred into a 350 ml blood collection bag (Baxter, Deerfield, IL, USA). Connection to the CliniMACS tubingset as well as the fully automated selection procedure was performed according to the instructions of the manufacturer. The purity and recovery of the isolated CD34 + cells, the contamination with T lymphocytes as well as the composition of cells within the negative fraction (unselected cells = total NC minus CD34 + cells) were assessed by flow cytometry.
Conditioning regimen
Informed consent was obtained from the parents. 
GVHD prophylaxis and cytokine stimulation after transplantation
None of the patients received prophylactic immunosuppression. Patients were evaluated daily for acute GVHD during hospitalization and at least once weekly as outpatients until day +100. Diagnosis of GVHD was based on WHO approved clinical signs. All patients received filgrastim (G-CSF) 5 g/kg/day subcutaneously starting at day +4 until white blood counts stabilized у5 ϫ 10 9 /l and erythropoietin (EPO) at a dosage of 150 IU/day by subcutaneous injection until reaching hemoglobin levels у10 g/dl without erythrocyte transfusions for 10 consecutive days.
Proliferation assays
A whole blood stimulation assay was used. 9 Briefly, various volumes (5, 10 and 20 l) of fresh, heparinized blood were diluted in microtiter plates to a final volume of 200 l with medium (RPMI-1640 with antibiotics and 10 −5 m 2-mercaptoethanol) containing the mitogens (all from Sigma, St Louis, MO, USA) phytohemagglutinin (PHA 20, 10, 5, 2.5 0.2 g/ml), concanavalin A (ConA 40, 20, 10, 5 g/ml), or pokeweed mitogen (PWM 160, 80, 40, 20 g/ml). Each culture was incubated for 72 h at 37°C in 5% CO 2 humidified air. The proliferative response was monitored by 3 HTdR uptake during the last 6-8 h of culture. The results were expressed as maximal counts per minute 
Results
Collection and manipulation of CD34 + cells
The median time between initial donor search and HLA confirmation of a suitable donor was 7 months (range 4-13). Two donor-recipient pairs (patients 1 and 2) were sexmatched. Patients 1 and 3 received HLA-identical grafts, whereas patient 2 received stem cells which were disparate at one HLA-locus (C-locus). Two donor leukaphereses yielded a median number of 10. Table 2 .
Engraftment and outcome (Table 3)
Patients received a median of 14.3 ϫ 10 6 CD34 + cells/kg body weight (range 11.7-24.3) with a median of 1.3 ϫ 10 4
CD3
+ cells/kg/body weight (range 0.57-5.8). All patients showed complete hematological reconstitution of donor origin. Median time to ANC у0.5 ϫ 10 9 /l was 7 days (range 7-12) and median time to platelets у20 ϫ 10 9 /l was 13 days (range 13-27). Reticulocytes appeared in the periphBone Marrow Transplantation eral blood at a median of 11 days (range [11] [12] [13] [14] . Repeated chimerism analysis of peripheral blood revealed permanently 100% donor hematopoiesis. Two patients (patients 1 and 3) are well and alive, whereas patient 2 who had a Clocus mismatched peripheral blood stem cell transplantation (PSCT) died at day +238 due to GVHD (grade III-IV) of the liver, lower gastrointestinal tract and skin despite intensive immunosuppression with CsA, MP, mycophenolate mofetil (MMF) and tacrolimus (FK506). Patient 1 developed pancytopenia with persistence of donor cells at day +591, after a trivial virus infection, which was successfully reversed by antithymocyte globulin (ATG) and cyclophosphamide followed by CD34 + -selected stem cells of the same donor.
GVHD
Acute GVHD (grade III-IV) of the liver, lower gastrointestinal tract and skin beginning on day +40, was diagnosed in patient 2, who had been previously transplanted with a 5/6 HLA-matched (C-locus-mismatch) UCB-graft, followed by an unrelated C-locus mismatched PSCT, which failed to respond high doses of prednisone, CsA, MMF and FK506 (Table 3) .
Immunologic reconstitution
A measurable number of circulating lymphocytes was detected in all patients 1 month after transplantation. The majority of early detectable lymphocytes was analyzed as CD56 + /CD16 + natural killer (NK) cells. 10 There was a correlation between the number of CD3 + /CD19 + lymphocytes occurring within 1 month after transplantation and the number of CD34 + cells transfused (correlation coefficient for CD3
+ cells: 0.95 and for CD19 + cells: 0.87) (Figure 1 ). The occurrence of CD8
+ cells was earlier than that of CD4 + cells, resulting in an inverted CD4 + /CD8 + ratio within the first 6 months after transplantation. In proliferative assays T lymphocytes showed an increasing response to polyclonal activators (PHA, ConA, PWM). The distribution of lymphocyte subtypes and mitogen-induced lymphocyte proliferation is depicted in Table 4 .
Discussion
Allogeneic stem cell transplantation is the only curative approach in children with SAA. Patients lacking an appropriate family donor may also benefit from immunosuppressive therapy. The results of mismatched family donor or matched unrelated bone marrow transplantations in patients failing such therapies, however, are not promising even though attempts have been made to overcome the risk of graft rejection as well as of GVHD by increasing the dose of the conditioning regimens and by reducing the number of transplanted T lymphocytes, respectively. 1, 11 Recently an [12] [13] [14] [15] [16] High purification of CD34
+ cells provides sufficient T cell depletion and therefore combines the advantage of high numbers of unrelated peripheral blood stem cells with a tolerable incidence of GVHD. Presently magnetic cell sorting of peripheral blood CD34
+ cells has been shown to be the most effective selection procedure in recovering high numbers of stem cells with high purity and low T cell numbers and therefore was used in our patients. [6] [7] [8] Donors were provided by the 'Deutsche Knochenmarsspenderdatei' (DKMS) (Tübingen, Germany). Two cell separations after mobilization with G-CSF yielded sufficient numbers of progenitors. Magnetic positive selection of CD34
+ cells resulted in excellent purity (median 99.2%, range 97.7-99.2%) with a very low contamination of residual T lymphocytes (р0.25 × 10 5 /kg). All patients received more than 10 × 10 6 CD34 + cells/kg body weight. Conditioning chemotherapy was well tolerated except for allergic reactions after ALG administration in two children. Patients showed rapid hematological reconstitution with sufficient lymphopoietic recovery of B and T lymphocytes within 3 months after transplantation (Figure 1 ). Patient 2 previously transplanted with a 5/6 matched UCB, followed by a C-locus mismatched PSC graft developed acute GVHD and died at day +238 due to GVHD (grade III-IV) of the liver, lower gastrointestinal tract and skin despite intensive immunosuppression with CsA, MP, MMF and FK506. The other two children are alive with a median follow-up of 15 months although patient 1 developed pancytopenia with persistence of 100% donor hematopoiesis 1 month after an unclassified viral infection at day +591. This aplastic episode, however, could be reversed successfully by a further course of ATG and cyclophosphamide followed by the retransfusion of highly purified positively selected CD34
+ cells from the original donor. To our knowledge, this experience represents the first We conclude that this procedure could be a promising alternative for children with SAA who lack a suitable related donor and have failed previous immunosuppressive therapies.
Note added in proof:
Meanwhile a fourth patient, a 7-year-old girl with refractory SAA was also given an unrelated peripheral stem cell transplant containing 7.85 × 10 6 highly purified CD34 + cells/kg (HLA-C mismatched at one locus) with 0.11 × 10 5 CD3
+ cells/kg following conditioning with thiotepa, cyclophosphamide, TLI and OKT-3. She also has uncomplicated engraftment up to now (day +60 post transplant).
